Exegenesis Bio, a global cell and gene therapy company, was founded with the mission to transform science into cures by developing innovative medicines based on gene therapy. The company focuses on both the Chinese and global markets, aiming to build a fully integrated gene and cell therapy pipeline targeting eye, CNS, and liver-directed diseases. Their core values emphasize efficiency, excellence, ownership, and a people-first approach. Key products and services include the AAVarta® AAV capsid in silico evolution discovery platform and the Constellation® AI-aided DNA expression cassette design platform.

Exegenesis Bio's team comprises experienced professionals in gene therapy drug design, preclinical studies, and clinical development. The company has attracted notable investors and partners within the biotechnology sector. Key achievements include the development of industry-leading R&D, manufacturing, and commercialization capabilities. Exegenesis Bio's impact is significant in advancing gene therapy technologies and providing new treatment options for previously untreatable conditions, positioning itself as a leader in the global biotech landscape.